SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Rosenberg D) "

Sökning: WFRF:(Rosenberg D)

  • Resultat 411-420 av 449
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
411.
  •  
412.
  •  
413.
  • Ray-Coquard, I., et al. (författare)
  • Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
  • 2020
  • Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 146:2, s. 439-448
  • Tidskriftsartikel (refereegranskat)abstract
    • AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with placebo. We report final results, including overall survival (OS). Patients with primary debulked International Federation of Gynaecology and Obstetrics (FIGO) stage IIB–IV newly diagnosed ovarian cancer were randomised 2:1 to receive carboplatin (area under the curve 5 or 6) plus paclitaxel (175 mg/m2) on day 1 every 3 weeks for six cycles combined with either nintedanib 200 mg or placebo twice daily on days 2–21 every 3 weeks for up to 120 weeks. Between December 2009 and July 2011, 1,366 patients were randomised (911 to nintedanib, 455 to placebo). Disease was considered as high risk (FIGO stage III with amp;gt;1 cm residuum, or any stage IV) in 39%. At the final analysis, 605 patients (44%) had died. There was no difference in OS (hazard ratio 0.99, 95% confidence interval [CI] 0.83–1.17, p = 0.86; median 62.0 months with nintedanib vs. 62.8 months with placebo). Subgroup analyses according to stratification factors, clinical characteristics and risk status showed no OS difference between treatments. The previously reported PFS improvement seen with nintedanib did not translate into an OS benefit in the nonhigh-risk subgroup. Updated PFS results were consistent with the primary analysis (hazard ratio 0.86, 95% CI 0.75–0.98; p = 0.029) favouring nintedanib. The safety profile was consistent with previous reports. © 2019 UICC
  •  
414.
  •  
415.
  •  
416.
  •  
417.
  •  
418.
  • Rosenberg, G. A., et al. (författare)
  • Consensus statement for diagnosis of subcortical small vessel disease
  • 2016
  • Ingår i: Journal of Cerebral Blood Flow and Metabolism. - : SAGE Publications. - 0271-678X .- 1559-7016. ; 36:1, s. 6-25
  • Tidskriftsartikel (refereegranskat)abstract
    • Vascular cognitive impairment (VCI) is the diagnostic term used to describe a heterogeneous group of sporadic and hereditary diseases of the large and small blood vessels. Subcortical small vessel disease (SVD) leads to lacunar infarcts and progressive damage to the white matter. Patients with progressive damage to the white matter, referred to as Binswanger's disease (BD), constitute a spectrum from pure vascular disease to a mixture with neurodegenerative changes. Binswanger's disease patients are a relatively homogeneous subgroup with hypoxic hypoperfusion, lacunar infarcts, and inflammation that act synergistically to disrupt the blood-brain barrier (BBB) and break down myelin. Identification of this subgroup can be facilitated by multimodal disease markers obtained from clinical, cerebrospinal fluid, neuropsychological, and imaging studies. This consensus statement identifies a potential set of biomarkers based on underlying pathologic changes that could facilitate diagnosis and aid patient selection for future collaborative treatment trials.
  •  
419.
  •  
420.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 411-420 av 449
Typ av publikation
tidskriftsartikel (293)
forskningsöversikt (12)
konferensbidrag (11)
annan publikation (2)
recension (1)
Typ av innehåll
refereegranskat (418)
övrigt vetenskapligt/konstnärligt (22)
populärvet., debatt m.m. (1)
Författare/redaktör
Eigen, G. (252)
Fassouliotis, D. (252)
Ferrer, A. (252)
Fuster, J. (252)
Hamacher, K. (252)
Ouraou, A. (252)
visa fler...
Salt, J. (252)
Stugu, B. (252)
Vrba, V. (252)
Dris, M. (251)
Elsing, M. (251)
Garcia, C. (251)
Kourkoumelis, C. (251)
Liebig, W. (251)
Masik, J. (251)
Nicolaidou, R. (251)
Parzefall, U. (251)
Weiser, C. (251)
Joram, C. (251)
Boonekamp, M. (250)
Bugge, L. (250)
Di Ciaccio, L. (250)
Leitner, R. (250)
Lipniacka, A. (250)
Maltezos, S. (250)
van Vulpen, I. (250)
Wicke, D. (250)
Benekos, N. (249)
Besson, N. (249)
Haug, S. (249)
Graziani, E. (247)
Abdallah, J (246)
Brenner, R. (246)
Canale, V. (246)
Chudoba, J. (246)
Di Simone, A. (245)
Passeri, A. (245)
Troncon, C. (245)
Andreazza, A. (244)
Moa, T. (244)
Moenig, K. (244)
Asman, B. (244)
Meroni, C. (243)
Onofre, A. (243)
Parodi, F. (243)
Hoffman, J. (242)
Anjos, N. (240)
Baroncelli, A. (240)
Morettini, P. (240)
Veloso, F. (240)
visa färre...
Lärosäte
Lunds universitet (278)
Uppsala universitet (172)
Karolinska Institutet (93)
Stockholms universitet (61)
Kungliga Tekniska Högskolan (54)
Göteborgs universitet (24)
visa fler...
Umeå universitet (16)
Luleå tekniska universitet (6)
Örebro universitet (6)
Linköpings universitet (6)
Chalmers tekniska högskola (4)
Sveriges Lantbruksuniversitet (2)
Linnéuniversitetet (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (448)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (160)
Medicin och hälsovetenskap (73)
Samhällsvetenskap (4)
Teknik (3)
Lantbruksvetenskap (1)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy